达格列净对老年2型糖尿病合并心力衰竭患者代谢水平的影响
Effects of Daggligin on Metabolism in Elderly Patients with Type 2 Diabetes and Heart Failure
摘要: 目的：探索达格列净(Dapagliflozin)对老年2型糖尿病合并心力衰竭患者血脂及尿酸代谢水平的影响。方法：选取2021年1月~2022年1月我院收治的105例老年2型糖尿病合并心力衰竭患者为研究对象，其中应用达格列净的患者55例，2型糖尿病合并心力衰竭未应用达格列净的患者50例，并且随访观察6个月。比较治疗前和治疗后3个月及6个月治疗组与安慰剂组的变化。结果：达格列净治疗组治疗后患者血脂及尿酸代谢水平均较前好转，且6个月较3个月效果更佳，与安慰剂组相比P < 0.05，有统计学意义。结论：达格列净治疗组治疗后患者血脂及尿酸水平均较前好转，且随时间延长，效果更佳。
Abstract: Objective: To explore the effect of dapagliflozin on blood lipid and uric acid metabolism in the aged patients with type 2 diabetes mellitus and heart failure. Methods: Select 105 aged patients with type 2 diabetes mellitus and heart failure admitted to our hospital from January 2021 to January 2022 as the subjects of study, including 55 patients who were treated with dapagliflozin and 50 pa-tients with type 2 diabetes mellitus and heart failure who were not treated with dapagliflozin, and were followed up for 6 months. Compare the changes between the treatment group and the placebo group before treatment and 3 and 6 months after treatment. Results: After treatment, the blood li-pid and uric acid metabolism levels of patients in the dapagliflozin treatment group were improved, and the effect of 6 months was better than that of 3 months, P < 0.05 compared with the placebo group, with statistical significance. Conclusion: The blood lipid and uric acid levels of patients in the dapagliflozin treatment group were improved after treatment, and the effect was better with time.
文章引用：孔越, 曹彩霞, 孙茜, 代黎明, 徐音飞, 潘晓彤. 达格列净对老年2型糖尿病合并心力衰竭患者代谢水平的影响[J]. 临床医学进展, 2023, 13(4): 5520-5526. https://doi.org/10.12677/ACM.2023.134781

参考文献

[1] Meigs, J.B. (2003) Epidemiology of Cardiovascular Complications in Type 2 Diabetes Mellitus. Acta Diabetologica, 40, S358-S361. [Google Scholar] [CrossRef] [PubMed]
[2] 黄妙玲, 黄莹, 郑晓斌. 达格列净联合胰岛素泵强化治疗新发糖尿病的效果及对胰岛β细胞功能的影响[J]. 解放军预防医学杂志, 2019, 37(3): 30-32.
[3] Gupta, P. and White, W.B. (2017) Cardiovascular Safety of Therapies for Type 2 Diabetes. Expert Opinion on Drug Safety, 16, 13-25. [Google Scholar] [CrossRef] [PubMed]
[4] Heidenreich, P.A., et al. (2022) AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Asso-ciation Joint Committee on Clinical Practice Guidelines. Circulation, 145, e895-e1032. [Google Scholar] [CrossRef] 
[5] 欧振飞, 于涛, 郭孝兹, 等. 达格列净对高龄女性射血分数保留的心力衰竭合并2型糖尿病患者的临床疗效评价[J]. 中华老年心脑血管病杂志, 2021, 23(4): 387-390.
[6] 贺红祥, 李贵民, 张文魁. 沙库巴曲缬沙坦联合达格列净治疗2型糖尿病合并心力衰竭患者的临床对照研究[J]. 实用心脑肺血管病杂志, 2021, 29(6): 99-104.
[7] 中国心力衰竭中心联盟专家委员会. 心力衰竭SGLT2抑制剂临床应用的中国专家共识[J]. 临床心血管病杂志, 2022, 38(8): 599-605.
[8] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版) [J]. 中华内分泌代谢杂志, 2021, 37: 311-398.
[9] The Emerging Risk Factors Col-laboration (2010) Diabetes Mellitus, Fasting Blood Glucose Concentration, and Risk of Vascular Disease: A Collabora-tive Meta-Analysis of 102 Prospective Studies. Lancet, 375, 103-105. [Google Scholar] [CrossRef] 
[10] Sun, Y.-N., Zhou, Y., Chen, X., Che, W.-S. and Leung, S.-W. (2014) The Efficacy of Dapagliflozin Combined with Hypoglycaemic Drugs in Treating Type 2 Diabetes Mellitus: Meta-Analysis of Randomised Controlled Trials. BMJ Open, 4. [Google Scholar] [CrossRef] [PubMed]
[11] Ptaszynska, A., et al. (2013) Effects of Dapagliflozin on Car-diovascular Risk Factors. Postgraduate Medicine, 125, 181-189. [Google Scholar] [CrossRef] [PubMed]
[12] 牟伦盼, 蒋建家, 张雅萍, 等. 达格列净与利格列汀对口服降糖药控制不佳的超重或肥胖2型糖尿病患者的疗效和安全性比较[J]. 中华糖尿病杂志, 2019, 11(3): 190-195.
[13] 陶然, 周金意, 苏健, 等. 江苏省成年人血脂异常与糖尿病关系[J]. 中国公共卫生, 2015, 31(5): 558-562.

为你推荐